ALNYLAM PHARMACEUTICALS INC (ALNY)       219.64  -6.56 (-2.9%)

219.64  -6.56 (-2.9%)

US02043Q1076 - Common Stock - After market: 219.64 0 (0%)

News Image
2 days ago - Alnylam Pharmaceuticals

Alnylam Anuncia a Aprovação de AMVUTTRA® (vutrisirana sódica) no Brasil para o Tratamento da Amiloidose Hereditária mediada por Transtirretina (hATTR) em Adultos

/PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), empresa líder em terapias de RNAi, acaba de anunciar que a Agência Nacional de Vigilância...

News Image
a month ago - Bloomberg

Alnylam Halts Work on Eye Drug, Citing New US Law Over Pricing

Alnylam Pharmaceuticals Inc. said it’s stopping work on a treatment for a rare eye disease because of a new US drug-pricing law with the potential to limit how much it could charge for the medication in the future.

News Image
2 months ago - Investor's Business Daily

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

News Image
2 months ago - The Motley Fool

3 Top Biotech Stocks Defying the Bear Market

Bear market, shmear market. These biotech stocks are soaring despite the market downturn.

News Image
3 months ago - Alnylam Pharmaceuticals, Inc.

Alnylam Announces New Management Appointments